Abstract
CETP is a lipid drug target under development for coronary heart disease (CHD) in both European and East Asian populations. Previous drug target Mendelian randomization (MR) studies conducted in East Asians failed to show a CHD effect, which has been interpreted as lack of effectiveness of CETP inhibition for CHD prevention in this population. Nevertheless, CETP inhibitors are currently being evaluated in East Asian participants. Capitalizing on recent increases in sample size of East Asian GWAS, we therefore conducted a drug target MR to estimate and compare ancestry-specific effects of on-target CETP inhibition. Employing cross-ancestry colocalization, we found strong evidence of a shared causal CETP variant affecting HDL-C in both populations, which was not observed for LDL-C. WE conducted drug target MR, scaled to a standard deviation increase in HDL-C, and found that lower CETP was associated with lower LDL-C, Lp[a], systolic blood pressure and pulse pressure in both groups, with more pronounced effects in Europeans individuals (interaction p-values < 1.9×10 − 3). Lower CETP was protective against CHD, angina, intracerebral haemorrhage and heart failure in both ancestries, for example for CHD in East Asians (OR 0.89, 95%CI 0.84;0.94) compared to Europeans (OR 0.95, 95%CI 0.92;0.99, interaction p-value = 0.05). In conclusion, on-target inhibition of CETP is anticipated to decrease cardiovascular disease in individuals of both European and East Asian ancestries.

This publication has 44 references indexed in Scilit: